title: Evaluation of clinical activity and safety of Daflon 500 mg in type 2 diabetic female patients.
abstract: BACKGROUND
  The incidence of cardiovascular disease in patients with type 2 diabetes mellitus is approximately twice as high as in the non-diabetic population.
  
  
  OBJECTIVE
  To investigate the hypoglycemic and hypocholesterolemic effects of Daflon(®) 500 mg (DF) administration together with its tolerability and efficacy in reducing the cardiovascular metabolic risk factors in female patients with type 2 diabetes.
  
  
  METHODS
  In a well-adequate controlled single-blinded randomized parallel design the tolerability and the efficacy of Daflon(®) (500 mg) either alone or with oral hypoglycemic, twice daily for 45 days, was studied in 36 female patients with type 2 diabetes.
  
  
  RESULTS
  None of the patients in the studied groups were reported to have any adverse events throughout the treatment period (45 days), liver and kidney function tests were within normal limits and there was no significant difference between the pre-treatment (day 0) and post-treatment (day 45) values. Female patients receiving Daflon(®) either alone or with oral hypoglycemic showed significant decrease in serum glucose; fructosamine; total cholesterol; LDL-cholesterol; triglycerides; malondialdehydes (as index of lipid peroxidation) and C-reactive protein (CRB) levels along with increase in the levels of nitric oxide and blood glutathione.
  
  
  CONCLUSIONS
  This study has shown that Daflon(®) (500 mg, twice daily for 45 days) is helpful in reducing glucose level and the risk of cardiovascular disease in type 2 diabetic patients.
  
  
  CONCLUSIONS
  Further clinical trials are essential for strengthening the evidence base on the role of this drug in the cardiovascular risk in diabetic patients.
authors: Department of Biochemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
authors: Sherine Maher
authors: SM
authors: Rizk
authors: Nagwa Ali
authors: NA
authors: Sabri
keywords: Cardiovascular disease risk; Daflon®; Diabetes mellitus
references: Int J Biochem Cell Biol. 2006;38(7):1134-45
references: 16427799
references: Angiology. 1997 Jan;48(1):93-8
references: 8995350
references: Endocrinol Metab Clin North Am. 2004 Jun;33(2):405-15
references: 15158526
references: Angiology. 1997 Jan;48(1):77-85
references: 8995348
references: Singapore Med J. 2005 Jul;46(7):322-4
references: 15968442
references: Int Angiol. 1995 Sep;14(3 Suppl 1):39-43
references: 8919264
references: Adv Intern Med. 1982;27:345-72
references: 7041546
references: Angiology. 1994 Jun;45(6 Pt 2):524-30
references: 8203782
references: Gac Med Mex. 2004 Jul-Aug;140(4):437-47
references: 15456154
references: Clin Chem. 1983 Jun;29(6):1113-5
references: 6851106
references: J Psychiatry Neurosci. 2004 Nov;29(6):414-6
references: 15644982
references: Angiology. 1994 Jun;45(6 Pt 2):566-73
references: 8203789
references: Diabetologia. 1993 Nov;36(11):1175-84
references: 8270133
references: Diabetes. 2007 Nov;56(11):2715-21
references: 17704302
references: Am J Clin Nutr. 1996 Jun;63(6):985S-990S
references: 8644698
references: Ann Clin Biochem. 1985 Jul;22 ( Pt 4):327-42
references: 3898972
references: Am J Cardiol. 2005 Aug 22;96(4A):8E-10E
references: 16098836
references: Diabetes. 2002 Mar;51(3):797-802
references: 11872682
references: Arterioscler Thromb Vasc Biol. 2005 Feb;25(2):274-8
references: 15514203
references: Cardiovasc Diabetol. 2003 Feb 12;2:2
references: 12628022
references: Diabetologia. 1993 Mar;36(3):229-33
references: 8462771
references: Int J Microcirc Clin Exp. 1997;17 Suppl 1:27-33
references: 9477042
references: Angiology. 1994 Jun;45(6 Pt 2):554-9
references: 8203787
references: Lipids. 1999 Jun;34(6):591-8
references: 10405973
references: J Nutr. 2004 Oct;134(10):2499-503
references: 15465737
references: Clin Chem. 1990 Jan;36(1):136-9
references: 2297905
references: Nitric Oxide. 2001 Feb;5(1):62-71
references: 11178938
references: Stroke. 1996 Jan;27(1):63-8
references: 8553405
references: Cardiovasc Drug Rev. 2006 Spring;24(1):33-50
references: 16939632
references: J Biol Chem. 1995 Jan 6;270(1):319-24
references: 7529227
references: Clin Chem. 1972 Jun;18(6):499-502
references: 4337382
references: Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1751-2
references: 12426198
references: Diabetes. 2003 Feb;52(2):453-62
references: 12540621
references: N Engl J Med. 2004 Jul 15;351(3):295-8; author reply 295-8
references: 15257563
references: Diabetes. 1990 Nov;39(11):1420-4
references: 2227114
references: Adv Exp Med Biol. 1995;369:39-48
references: 7598015
references: Diabetes Care. 2002 May;25(5):894-9
references: 11978687
references: Lancet. 1976 Nov 6;2(7993):1009-12
references: 62224
references: Clin Chem. 1974 Apr;20(4):470-5
references: 4818200
references: J Lab Clin Med. 1963 May;61:882-8
references: 13967893
references: Circulation. 2003 Jan 28;107(3):499-511
references: 12551878
references: Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):29-38
references: 15539615
references: Biochem J. 1992 Nov 15;288 ( Pt 1):303-7
references: 1445275
references: Methods Enzymol. 1996;268:142-51
references: 8782580
references: Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1323-8
references: 12171795
references: J Nutr. 1999 Jun;129(6):1182-5
references: 10356084
references: N Engl J Med. 1989 Apr 6;320(14):915-24
references: 2648148
references: BMJ. 2000 Aug 12;321(7258):405-12
references: 10938048
references: Diabetes Care. 2004 Jun;27(6):1496-504
references: 15161808
references: Anal Biochem. 1978 May;86(1):271-8
references: 655387
references: Angiology. 2000 Jan;51(1):19-23
references: 10667639
references: Br Med J (Clin Res Ed). 1983 Sep 24;287(6396):867-70
references: 6412862
references: Circulation. 1998 May 5;97(17):1695-701
references: 9591763
references: BMC Pharmacol. 2005 Jan 31;5:2
references: 15683547
references: Ann Rheum Dis. 1986 Jan;45(1):44-6
references: 3954457
references: Diabetes Care. 1995 Feb;18(2):258-68
references: 7729308
references: Curr Hypertens Rep. 2004 Apr;6(2):85-9
references: 15010009